약물 및 유전자 전달 시스템 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Drugs and Gene Delivery Systems Market size is expected to reach USD 11.34 Billion in 2034 from USD 4.60 Billion (2025) growing at a CAGR of 10.56% during 2026-2034.

The global drugs and gene delivery systems market is witnessing significant growth due to the increasing development of advanced therapeutics and the rising demand for targeted drug delivery technologies. Gene delivery systems play a crucial role in modern biotechnology and gene therapy by enabling the efficient transfer of genetic material into cells for therapeutic purposes. The growing prevalence of chronic diseases and genetic disorders is driving the demand for innovative delivery technologies that improve treatment effectiveness.

One of the key drivers of this market is the rapid advancement in gene therapy and biotechnology research. Pharmaceutical and biotechnology companies are investing heavily in the development of viral and non-viral delivery systems to enhance treatment precision and safety. In addition, the increasing focus on personalized medicine and targeted therapies is accelerating the adoption of advanced drug and gene delivery platforms in clinical applications.

Looking ahead, the market is expected to expand significantly as gene-based treatments gain wider regulatory approval and clinical adoption. Continuous technological innovation in nanotechnology-based delivery systems and biomaterials will further enhance treatment efficiency. Increasing investments in biotechnology research and expanding healthcare infrastructure in emerging markets are also expected to create strong growth opportunities in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Delivery System

• Drug Delivery Systems (lntrauterine Implants, Prodrug Implants, Polymeric Drug Delivery, Targeted Drug Delivery)

By Gene Delivery Systems

• Viral Gene Delivery
• Non-viral Gene Delivery
• Combined Hybrid System

By Route of Administration

• Oral
• Injectable
• Inhalation
• Transdermal
• Ocular
• Nasal
• Topical

By Application

• Infectious Diseases
• Oncology
• Ophthalmology
• Urology
• Diabetes
• CNS
• Others

COMPANIES PROFILED

• Novartis AG, Amgen inc, Oxford BioMedica plc, SIBIONO, Shanghai Sunway Biotech Co Ltd, F HoffmannLa Roche Ld, Pfizer Inc, Bayer AG, Johnson Johnson Services Inc, Becton, Dickinson and Company, AstraZeneca plc, Baxter International Inc, Boston Scientific Corporation, GenVivo Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY DELIVERY SYSTEM 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Delivery System
• 4.2. Drug Delivery Systems (lntrauterine Implants, Prodrug Implants, Polymeric Drug Delivery, Targeted Drug Delivery) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY GENE DELIVERY SYSTEMS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gene Delivery Systems
• 5.2. Viral Gene Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-viral Gene Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Combined Hybrid System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Transdermal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Ocular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Nasal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Urology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DRUGS AND GENE DELIVERY SYSTEMS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Delivery System
  • 8.2.2 By Gene Delivery Systems
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Application
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Delivery System
  • 8.3.2 By Gene Delivery Systems
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Application
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Delivery System
  • 8.4.2 By Gene Delivery Systems
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Application
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Delivery System
  • 8.5.2 By Gene Delivery Systems
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Application
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Delivery System
  • 8.6.2 By Gene Delivery Systems
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Application
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DRUGS AND GENE DELIVERY SYSTEMS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Novartis AG
  • 10.2.2 Amgen Inc
  • 10.2.3 Oxford BioMedica Plc
  • 10.2.4 SIBIONO
  • 10.2.5 Shanghai Sunway Biotech Co. Ltd
  • 10.2.6 F. Hoffmann-La Roche Ld
  • 10.2.7 Pfizer Inc
  • 10.2.8 Bayer AG
  • 10.2.9 Johnson & Johnson Services Inc
  • 10.2.10 Becton, Dickinson And Company
  • 10.2.11 AstraZeneca Plc
  • 10.2.12 Baxter International Inc
  • 10.2.13 Boston Scientific Corporation
  • 10.2.14 GenVivo Inc